2nd Speech and Swallowing in Parkinson's Disease School

London, United Kingdom – July 6-7, 2018

2nd Speech and Swallowing in Parkinson's Disease School

London, United Kingdom – July 6-7, 2018

The 2nd Speech and Swallowing in PD School takes place in London, United Kingdom, July 6-7, 2018.Course Directors

Elina Tripoliti, PhD and Patricia Limousin, MD, PhD

Course Description

Dysarthria in Parkinson’s disease (PD) is primarily characterized by hypophonia and dysprosody. It worsens during the disease progression with a poor and variable response to pharmacological and /or neurosurgical treatments. Swallowing and saliva production is often affected, with impact on quality of life and social participation.

The main objective of the 2nd Speech and Swallowing in Parkinson’s Disease School is to provide an opportunity for clinicians and researchers interested in speech, swallowing and saliva problems to share the most recent knowledge on the clinical management of these areas. The four main themes are:

  • Use of technology for assessment and treatment
  • Atypical parkinsonism
  • Social participation (how to measure and manage effectively)
  • Pharmacological and surgical management of PD

The program is designed as a 2-day school in order to provide an opportunity for small group workshops and patient participation.

We look forward to an inspiring event, and a special opportunity to discuss speech, swallowing and saliva issues in PD and parkinsonism in a multidisciplinary team.

Learning Objectives
  • Discuss the neurological bases of normal speech production and speech impairment in PD and atypical parkinsonism
  • Assess speech impairment and swallowing impairment in PD and its implications on social participation
  • Select and design a rehabilitation program targeting speech and/or swallowing impairments in PD patients
  • Consider technological advances for assessing and treating and monitoring speech and swallowing problems
  • Appreciate the challenge of treating speech impairment as part of a multidisciplinary team
  • Consider patient-reported outcome measures as part of the evaluation and follow-up program of management
  • Identify how and when speech therapy can be fully effective according to disease progression and in association with medical and/or surgical treatments
Recommended Audience

Speech therapists and speech pathologists; neurologists and ENTs; heath professionals specialized in PD management; speech scientists, and neuroscientists


The Institute of Neurology
National Hospital for Neurology and Neurosurgery
33 Queen Square, London, WC1N 3BG
United Kingdom

Continuing Education Credits – Accreditation Statement

Asha Continuing EducationLSVT Global is approved by the Continuing Education Board of the American Speech-Language-Hearing Association (ASHA) to provide continuing education activities in speech-language pathology and audiology. See course information for number of ASHA CEUs, instructional level and content area. ASHA CE Provider approval does not imply endorsement of course content, specific products or clinical procedures.

This course is offered for 1.25 CEUs (Advanced level; Professional area).

Please click to view the full ASHA Brochure


MDS is able to provide participants with a Letter of Support and any course-related documentation needed to assist in obtaining a visa. Please note that MDS is unable to contact the Embassy on your behalf. It is the responsibility of each participant to make the necessary arrangements related to this process. However, if the official handling your application needs further clarification, please contact education@movementdisorders.org.


We use cookies to give you the best possible experience with our website. These cookies are also used to ensure we show you content that is relevant to you. If you continue without changing your settings, you are agreeing to our use of cookies to improve your user experience. You can click the cookie settings link on our website to change your cookie settings at any time. Note: The MDS site uses related multiple domains, including mds.movementdisorders.org and mds.execinc.com. This cookie policy only covers the primary movementdisorders.org and mdscongress.org domain. Please refer to the MDS Privacy Policy for information on how to configure cookies for all other domains on the MDS site.
Cookie PolicyPrivacy Notice